Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-CONIC: Imatinib to convert triple negative breast cancer into ER-positive
2020-005200-19Phase 2Active
- Sponsor
- Region Västra Götaland
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in triple-negative breast cancer (TNBC), sponsored by Region Västra Götaland. Primary endpoint: ER-positivity at surgery. Started Dec 2020; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-005200-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005200-19.